Overview

LRAs United as a Novel Anti-HIV Strategy.

Status:
Completed
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
A translational proof of concept study in humans on the primary research question whether novel anti-human immunodeficiency virus (HIV) latency strategies, including a BAF inhibitor and a histone deacetylase inhibitor, result in HIV reservoir reduction in HIV patients on antiretroviral therapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Erasmus Medical Center
Treatments:
Pyrimethamine
Valproic Acid